Bridgewater, NJ (GLOBE NEWSWIRE) - Clinical Genomics, a leading provider of liquid biopsy cancer testing solutions, today announced the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Clinical Genomics Pathology Inc., based on results of a recent on-site inspection as part of CAP's Accreditation Programs. With this accreditation, Clinical Genomics Pathology, Inc. joins an elite group of globally recognized facilities that operate at the highest level of quality laboratory standards. Clinical Genomics Pathology, Inc. is the sole provider of COLVERA™, a liquid biopsy ctDNA assay used to detect residual disease and recurrent disease in patients previously diagnosed with colorectal cancer.
"From day one, Clinical Genomics has been committed to quality in every aspect of our performance,” noted Robert Boorstein, MD, PhD, Laboratory Medical Director. “Accreditation by CAP, and our ongoing commitment to adhere to the standards of the College, provides a framework to maintain and improve upon every aspect of our clinical performance on a daily basis."
"This recognition by the College is a testament to our laboratory’s commitment to delivering world-class patient health care," added John P. Alsobrook II, PhD, DABCC, FACB, Laboratory Site Director and Vice President of Operations for Clinical Genomics Pathology. “Clinicians now have additional assurance that the results of our test are reliable and of the highest quality.”
The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal-to or more-stringent-than the government's own inspection program.
During the CAP accreditation process, designed to ensure the highest standard of care for all laboratory patients, inspectors examine the laboratory's records and quality control procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management.
About the College of American Pathologists
As the world’s largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, read the CAP Annual Report at cap.org.
About Clinical Genomics
Clinical Genomics is dedicated to improving patient outcomes through early detection of colorectal cancer. Clinical Genomics products span the full spectrum of colorectal cancer testing, including InSure® FIT™, a fecal immunochemical test for screening in healthy adults, to COLVERA™, a proprietary liquid biopsy blood test identifying circulating tumor DNA in patient’s post-treatment for early detection of recurrence and residual disease. Clinical Genomics is committed to developing and delivering solutions that provide physicians and their patients with information to help guide earlier and better treatment decisions in cancer care management. Clinical Genomics continues to apply its proprietary innovation in molecular pathology to commercialize other diagnostic tools in other cancer types.
© Copyright 2017, GlobeNewswire, Inc. All Rights Reserved.
SOURCE: Clinical Genomics